About this event

  • Date and time Wed 27 Jan 2021 from 4:30pm to 6:00pm
  • Location Online
  • Organised by Endocrinology and Diabetes

This 3-part webinar series will explore the challenges in managing heart failure and renal disease in diabetes. It will promote understanding and communication between general practitioners, cardiologists, nephrologists and endocrinologists working together to combat heart failure and diabetes.

In this second webinar, join us to understand the newest inhibitors and receptor agonists in the treatment of diabetes put in place for cardio-renal protection.

During this webinar you will:

  • Learn how GLP-1 receptor agonists fit into cardiovascular risk management 
  • Understand the benefits of GLP-1 receptor agonists beyond glycaemic control 
  • Discover the renoprotective effects of SGLT2i

Have you registered for part 1 and 3 yet? Sign up to them now and get part 3 for free. Please email events@rsm.ac.uk to claim your free place:

A certificate of attendance and CPD certificate with 1 CPD credit(s) per webinar of this series will be issued to those joining the webinars live. Certificates of attendance for CPD will be automatically issued after 7 days, but only where a delegate watches the webinar live in its entirety. 

10 x bursary places are available for this series. Please email endocrinology@rsm.ac.uk to claim your place.

Join in the conversation online
Follow us on Twitter: @RoySocMed 

We would like to thank our sponsors Eli Lilly and Company and Novo Nordisk for their support of this webinar. Please note that the scientific programme and content has not been influenced in any way by the sponsors.

Key speakers

Professor John Deanfield

Professor of Cardiology, University College London

Speaker's biography

John Deanfield is Professor of Cardiology at University College London (UCL) and Consultant Cardiologist at the Barts Heart Centre (BHC) London UK.   He is the Director of National Institute for Cardiovascular (CV) Outcomes Research (NICOR) which incorporates the national databases for cardiovascular outcomes. Professor Deanfield undertook his undergraduate training at Churchill College, Cambridge and the Middlesex Hospital, London and subsequently trained at the Hammersmith and Great Ormond Street Hospitals. His principal interests are vascular medicine, opportunities for lifetime management of cardiovascular risk and large scale cardiovascular outcomes research.  He has been at the forefront in describing the impact of obesity, cholesterol, diabetes, smoking and other risk factors on health in later life, through coordination of multiple large longitudinal cardiovascular studies in population throughout lifetime. He Chaired the Joint British Societies (JBS3) National Guidelines for Cardiovascular Disease Prevention (2014) and in collaboration with Public Health England, NHS Choices and NHS England led the development of the public facing Heart Age Tool first launched in January 2015.   He was awarded the British Cardiac Society McKenzie Award, and the John Hopkins All Children’s Hospital Decades of Service Award in 2017.  He currently Chairs the UK’s National Health Check Programme Review (2020) and is Chief Medical Advisor to the new national Early Disease Detection programme (2020). Professor Deanfield serves on many international advisory boards and is a member of the editorial boards of several major CV journals, as well as Associate Editor of the European Heart Journal. He has published numerous articles in leading medical and scientific journals such as New England Journal of Medicine, The Lancet, Circulation and European Heart Journal.  Papers published: 484 Citations: >100K H index: 131.

Professor Gerry McKay

Consultant Physician and Clinical Pharmacologist, Glasgow Royal Infirmary

Speaker's biography

Professor Gerry McKay is a Consultant Physician & Clinical Pharmacologist at Glasgow Royal Infirmary, an Honorary Clinical Assoicate Professor at the University of Glasgow and Visiting Professor at the University of Strathclyde. He is currently lead clinician for an evolving Department of Diabetes, Endocrinology and Clinical Pharmacology in Glasgow Royal Infirmary. He contributes to the provision of diabetes care in the north east of Glasgow specialising in the care of those with Type 2 diabetes including being lead for a specialist clinical for patients with diabetic nephropathy. He has a commitment to safe and rational prescribing with involvement in undergraduate and postgraduate education.  He was involved in the development off SIGN guidelines including the therapeutics update in 2017. He has co-edited a book on SGLT-2 inhibitors, the last 2 editions of Lecture Notes in Clinical Pharmacology & Therapeutics and published many papers in the area of therapeutics and diabetes.

Professor David Wheeler

Professor of Kidney Medicine, University College London  

Speaker's biography

Clinician scientist based at the Royal Free Hospital with an interest in chronic kidney disease (CKD) and its complications. Has been involved in many randomised controlled trials in patients with CKD assessing lipid lowering therapies, calcimimetics, intravenous iron and SGLT2 inhibitors. Co-principle investigator of the DAPA-CKD trial.


View the programme

Welcome and introduction 

Dr Ketan Dhatariya, Consultant in Diabetes and Endocrinology and Honorary Professor of Medicine, Norfolk and Norwich University Hospitals NHS Foundation Trust and Dr Abdul Lakhdar, Consultant Endocrinologist, Barts Health NHS Trust 

Diabetes and cardiovascular disease: Time for a multifactorial approach

Professor John Deanfield, Professor of Cardiology, University College London

The multi-factorial benefits of GLP-1 RAs beyond glycaemic control

Professor Gerry McKay, Consultant Physician and Clinical Pharmacologist, Glasgow Royal Infirmary

The renoprotecive effects of SGLT2i

Professor David Wheeler, Professor of Kidney Medicine, University College London

Panel discussion
Close of meeting




More from this series:

EDP50 Promo
Webinar CPD

Kidneys, heart and diabetes: Science and practice – Part 1

This 3-part webinar will explore the challenges in managing heart failure and renal disease in diabetes.

In this first webinar, experts in their field unite to address recent clinical trial results for the management of thrombosis in diabetes and discuss new practises in the management of heart failure.

EDP50 Promo
Webinar CPD

Kidneys, heart and diabetes: Science and practice – Part 3

This 3-part webinar series will explore the challenges in managing heart failure and renal disease in diabetes. 

In this final webinar, specialists unite to discuss adopting a multifactorial approach for therapeutics and whether cardiologists and nephrologists should be able to prescribe sodium glucose transporter-2 inhibitors (SGLT2i).

*Registration for this webinar will close 2 hours prior to the start time. You will receive the webinar link 2 hours before the meeting. Late registrations will not be accepted. 

Webinar recordings will be available for registered delegates up to 30 days after the live webinar, via Zoom. The link will be sent 24 hours after the webinar takes place. 

This webinar will be recorded and stored by the Royal Society of Medicine and may be distributed in future on various internet channels.